<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04281472</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-113-1802</org_study_id>
    <secondary_id>2019-003076-39</secondary_id>
    <nct_id>NCT04281472</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)</brief_title>
  <acronym>ADHERE</acronym>
  <official_title>A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>argenx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>argenx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation&#xD;
      of efgartigimod in adults with CIDP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">August 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage A: Percentage of patients with confirmed evidence of clinical improvement(ECI)</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage B: Time to first adjusted INCAT deterioration compared to Stage B baseline</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stage A: Time to initial confirmed ECI</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Change from Stage A baseline over time in adjusted INCAT score</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Change from Stage A baseline over time in Medical Research Council (MRC) Sum score</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Change from Stage A baseline over time in I-RODS disability scores</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Change from Stage A baseline over time in TUG score</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Change from Stage A baseline over time in mean grip strength</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Exposure adjusted occurrence of treatment-emergent (serious) adverse events</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Incidence of clinically significant laboratory abnormalities</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Pre-dosing efgartigimod serum concentrations over time</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Changes of serum IgG levels over time</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage A: Percentage of patients with and titers of binding antibodies towards efgartigimod and/or rHuPH20 and the presence of neutralizing antibodies against efgartigimod and/or rHuPH20</measure>
    <time_frame>Up to 12 weeks during the open-label stage A</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Time to CIDP disease progression</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
    <description>Time to CIDP disease progression is defined by the time from first dose of double-blind IMP to the first I-RODS score decrease ≥4 points compared to Stage B baseline using the centile metric.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Percentage of patients with improved functional level compared to Stage B baseline</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Change from Stage B baseline over time in adjusted INCAT score</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Change from Stage B baseline over time in MRC Sum score</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Change from Stage B baseline over time in 24-item I-RODS disability score</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Change from Stage B baseline over time in TUG score</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Change from Stage B baseline over time in mean grip strength</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Time to 10% decrease in the 24-item I-RODS</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Exposure adjusted occurrence of treatment-emergent adverse events and serious adverse events</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Incidence of clinically significant laboratory abnormalities</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Pre-dosing efgartigimod serum concentrations over time</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Changes of serum IgG levels over time</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage B: Percentage of patients with and titers of binding antibodies towards efgartigimod and/or rHuPH20 and the presence of neutralizing antibodies against efgartigimod and/or rHuPH20</measure>
    <time_frame>Up to 48 weeks during the randomized placebo-controlled stage B</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</condition>
  <arm_group>
    <arm_group_label>efgartigimod PH20 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients receiving efgartigimod PH20 SC in both stage A as stage B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients receiving efgartigimod PH20 SC during stage A and receiving placebo in stage B</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>efgartigimod PH20 SC in stage B</intervention_name>
    <description>Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>efgartigimod PH20 SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo in stage B</intervention_name>
    <description>Stage A: N/A, stage B: placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand the requirements of the trial, provide written informed consent&#xD;
             (include consent for the use and disclosure of research-related health information),&#xD;
             willingness and ability to comply with the trial protocol procedures (including&#xD;
             required trial visits)&#xD;
&#xD;
          2. Male or female patient aged 18 years or older, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          3. Diagnosed with probable or definite CIDP according to criteria of the European&#xD;
             Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS 2010),&#xD;
             progressing or relapsing forms.&#xD;
&#xD;
          4. CIDP Disease Activity Status (CDAS) score ≥2 at screening.&#xD;
&#xD;
          5. INCAT score ≥2 at the first run-in visit (for patients entering run-in) or stage A&#xD;
             baseline (for treatment-naïve patients with documented evidence for worsening on the&#xD;
             total adjusted INCAT disability score within 3 months prior to screening). Patients&#xD;
             with an INCAT score of 2 at trial entry must have this score exclusively from the leg&#xD;
             disability score; for patients with an INCAT score of ≥3 at trial entry, there are no&#xD;
             specific requirements for arm or leg scores.&#xD;
&#xD;
          6. Fulfilling any of the following treatment conditions:&#xD;
&#xD;
               -  Currently treated with pulsed corticosteroids, oral corticosteroids equivalent to&#xD;
                  prednisolone/prednisone ≤10mg/day, and/or IVIg or SCIg, if this treatment has&#xD;
                  been started within the last 5 years before screening, and the patient is willing&#xD;
                  to discontinue this treatment at the first run-in visit; or&#xD;
&#xD;
               -  Without previous treatment (treatment-naive); or&#xD;
&#xD;
               -  Treatment with corticosteroids and/or IVIg or SCIg discontinued at least 6 months&#xD;
                  prior to screening Note: Patients not treated with monthly or daily&#xD;
                  corticosteroids, IVIg or SCIg for at least 6 months prior to screening are&#xD;
                  considered as equal to treatment-naïve patients.&#xD;
&#xD;
          7. Women of childbearing potential who have a negative pregnancy test at screening and a&#xD;
             negative urine pregnancy test up to Stage A baseline.&#xD;
&#xD;
          8. Women of childbearing potential must use a highly effective or acceptable method of&#xD;
             contraception from screening to 90 days after the last administration of IMP&#xD;
&#xD;
          9. Male patients agree not to donate sperm during the trial period and 90 days&#xD;
             thereafter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pure sensory atypical CIDP (EFNS/PNS definition).&#xD;
&#xD;
          2. Polyneuropathy of other causes, including the following: Multifocal motor neuropathy;&#xD;
             Monoclonal gammopathy of uncertain significance with anti-myelin associated,&#xD;
             glycoprotein immunoglobulin M (IgM) antibodies; Hereditary demyelinating neuropathy;&#xD;
             Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change&#xD;
             syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to&#xD;
             diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or&#xD;
             toxin-induced polyneuropathy.&#xD;
&#xD;
          3. Any other disease that could better explain the patient's signs and symptoms.&#xD;
&#xD;
          4. Any history of myelopathy or evidence of central demyelination.&#xD;
&#xD;
          5. Current or past history (within 12 months of screening) of alcohol, drug or medication&#xD;
             abuse.&#xD;
&#xD;
          6. Severe psychiatric disorder (such as severe depression, psychosis, bipolar disorder),&#xD;
             history of suicide attempt, or current suicidal ideation that in the opinion of the&#xD;
             investigator could create undue risk to the patient or could affect adherence with the&#xD;
             trial protocol.&#xD;
&#xD;
          7. Patients with clinically significant active or chronic uncontrolled bacterial, viral,&#xD;
             or fungal infection at screening, including patients who test positive for an active&#xD;
             viral infection at screening with: Active Hepatitis B Virus (HBV): serologic panel&#xD;
             test results indicative of an active (acute or chronic) infection; Active Hepatitis C&#xD;
             Virus (HCV): serology positive for HCV-Ab; Human Immunodeficiency Virus (HIV) positive&#xD;
             serology associated with an Acquired Immune Deficiency Syndrome (AIDS)-defining&#xD;
             condition or with a cluster of differentiation 4 (CD4) count ≤200 cells/mm3.&#xD;
&#xD;
          8. Total IgG level &lt;6 g/L at screening.&#xD;
&#xD;
          9. Treatment with the following: Within 3 months (or 5 half-lives of the drug, whichever&#xD;
             is longer) before screening: plasma exchange or immunoadsorption, any concomitant&#xD;
             Fc-containing therapeutic agents or other biological, or any other investigational&#xD;
             product; Within 6 months before screening: rituximab, alemtuzumab, any other&#xD;
             monoclonal antibody, cyclophosphamide, interferon, tumor necrosis factor-alpha&#xD;
             inhibitors, fingolimod, methotrexate, azathioprine, mycophenolate, any other&#xD;
             immunomodulating or immunosuppressive medications, and oral daily corticosteroids &gt;10&#xD;
             mg/day. Note: Patients using IVIg, SCIg, pulsed corticosteroids, and oral daily&#xD;
             corticosteroids ≤10 mg/day can be included.&#xD;
&#xD;
         10. Pregnant and lactating women and those intending to become pregnant during the trial&#xD;
             or within 90 days after last IMP administration.&#xD;
&#xD;
         11. Patients with any other known autoimmune disease that, in the opinion of the&#xD;
             investigator, would interfere with an accurate assessment of clinical symptoms of&#xD;
             CIDP.&#xD;
&#xD;
         12. Patients who received a live-attenuated vaccine fewer than 28 days before screening.&#xD;
             Receiving an inactivated, sub-unit, polysaccharide, or conjugate vaccine any time&#xD;
             before screening is not exclusionary.&#xD;
&#xD;
         13. Patients who have a history of malignancy unless deemed cured by adequate treatment&#xD;
             with no evidence of recurrence for ≥3 years before the first IMP administration.&#xD;
             Patients with the following cancer can be included anytime: Adequately treated basal&#xD;
             cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ&#xD;
             of the breast, or Incidental histological finding of Prostate cancer (TNM [tumor,&#xD;
             nodes, and metastases classification] stage T1a or T1b).&#xD;
&#xD;
         14. Patients who previously participated in a trial with efgartigimod and have received at&#xD;
             least one administration of IMP.&#xD;
&#xD;
         15. Patients with known medical history of hypersensitivity to any of the ingredients of&#xD;
             IMP.&#xD;
&#xD;
         16. Patients with clinical evidence of other significant serious disease or patients who&#xD;
             underwent a recent or have a planned major surgery, or any other reason which could&#xD;
             confound the results of the trial or put the patient at undue risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sabine Coppieters, MD</last_name>
    <phone>+1 857-350-4834</phone>
    <email>ClinicalTrials@argenx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator site 100</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233-2110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 43</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 37</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 6</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 97</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 114</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 10</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 1</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 45</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 99</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 9</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 46</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 105</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 104</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 130</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 125</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 98</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 58</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 113</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 8</name>
      <address>
        <city>Patchogue</city>
        <state>New York</state>
        <zip>11772</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 124</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 108</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 48</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0525</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 103</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 35</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 2</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 34</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 51</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 74</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 131</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Coppieters, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 126</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 115</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 52</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 59</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 61</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 106</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 60</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 26</name>
      <address>
        <city>Sofia</city>
        <zip>1680</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>Clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 62</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500-03</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 64</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 63</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 50</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 53</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 69</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 68</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 49</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 67</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 66</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 65</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 7</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 112</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 71</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 72</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 70</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 44</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 73</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 132</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Coppieters, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 18</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 20</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 21</name>
      <address>
        <city>H̱olon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 38</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 11</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 77</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 82</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 79</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 107</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 75</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 80</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 78</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 76</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 81</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 118</name>
      <address>
        <city>Bunkyō-Ku</city>
        <zip>113-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 83</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 90</name>
      <address>
        <city>Chuo Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 110</name>
      <address>
        <city>Fuchū</city>
        <zip>183-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 102</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 117</name>
      <address>
        <city>Itabashi</city>
        <zip>173-8606</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 88</name>
      <address>
        <city>Kawaguchi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 133</name>
      <address>
        <city>Kawasaki</city>
        <zip>2016-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Coppieters, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 85</name>
      <address>
        <city>Kodaira</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 128</name>
      <address>
        <city>Kyoto</city>
        <zip>616-8255</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 86</name>
      <address>
        <city>Mibu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 89</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 54</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 84</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 87</name>
      <address>
        <city>Sagamihara</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 116</name>
      <address>
        <city>Sapporo</city>
        <zip>0608638</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antionio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 119</name>
      <address>
        <city>Shinjuku-Ku</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 127</name>
      <address>
        <city>Yokohama</city>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 16</name>
      <address>
        <city>Riga</city>
        <zip>1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 109</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 91</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 13</name>
      <address>
        <city>Białystok</city>
        <zip>15-402</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 15</name>
      <address>
        <city>Katowice</city>
        <zip>40-650</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 17</name>
      <address>
        <city>Kraków</city>
        <zip>30-539</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 22</name>
      <address>
        <city>Kraków</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 12</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 19</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 92</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 14</name>
      <address>
        <city>Łódź</city>
        <zip>90-324</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigation site 121</name>
      <address>
        <city>Braşov</city>
        <zip>500299</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 120</name>
      <address>
        <city>Bucharest</city>
        <zip>011302</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 123</name>
      <address>
        <city>Constanţa</city>
        <zip>900591</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 122</name>
      <address>
        <city>Timişoara</city>
        <zip>300723</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 42</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 101</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 55</name>
      <address>
        <city>Moscow</city>
        <zip>117186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 56</name>
      <address>
        <city>Moscow</city>
        <zip>117186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 93</name>
      <address>
        <city>Perm</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 40</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 111</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 39</name>
      <address>
        <city>Saransk</city>
        <zip>430032</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 47</name>
      <address>
        <city>Belgrad</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 94</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 27</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 95</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 25</name>
      <address>
        <city>Córdoba</city>
        <zip>14011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 24</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 41</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 23</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 32</name>
      <address>
        <city>Dniprodzerzhyns'k</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 30</name>
      <address>
        <city>Dnipro</city>
        <zip>49069</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 28</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 33</name>
      <address>
        <city>Kharkiv</city>
        <zip>61058</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 31</name>
      <address>
        <city>Kyiv</city>
        <zip>21000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 57</name>
      <address>
        <city>Luts'k</city>
        <zip>43024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 34</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 96</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 29</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator site 129</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://adherecidpstudy.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

